Multiple component pharmaceutical solids attract special attention as upgraded remedies that provide complemented or synergetic actions often accompanied by the improved pharmaceutical profile (stability, solubility, biocompatibility) in comparison with single pharmacophore [1]. Using drug cocktails combining two or more therapeutic agents with different modes of action and non-overlapping toxicities becomes a common practice in the clinical treatment of cancer and other diseases [2]. We report here two ionic supramolecular complexes obtained by co-crystallization of hexamminecobalt (III) chloride, [Co(NH3)6]Cl3 (―Cohex‖), that reveals a wide spectrum of antiviral properties [3], with two pharmacophores, NSAID mefenamic acid (2-(2,3-dimethylphenyl)aminobenzoic acid (Hmef) [4] and 4-amino-1,2,5-oxadiazole-3-carboxylic acid (Hoxa). The crystals with compositions [Co(NH3)6][mef]2Cl•2H2O (1) and [Co(NH3)6][oxa]2Cl•H2O (2) represent H-bonded systems with inclusion of mef or oxa as anionic components in the matrix of [Co(NH3)6]2Cl•2H2O due to the metal‘s second-sphere coordination (Figure). Figure. ORTEP drawings for the components in 1 (left) and 2 (right). The triclinic (1) and monoclinic (2) monocrystals are characterized by unit cell parameters a=7.0746(4), b=7.1361(5), c=19.1363(12) Å, α=80.552(5), β=85.770(5), γ=19.1363(12)°; a=7.0175(3), b=18.9329(9), c=7.4775(5) Å, β=105.231(5)°. The details of supramolecular architecture in the solid state are discussed. In conclusion, two given examples show that Cohex may be potentially useful in a combination drug therapy.